Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217061 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL24680877 | 0.88 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL12120419 | 0.88 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL20521564 | 0.88 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| Bromide SCHEMBL1306727 | 0.88 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL1088444 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| SCHEMBL15108737 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3RENCYP2D6 | |
| SCHEMBL23589136 | 0.80 | SLC6A2 (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL12120357 | 0.79 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL19292100 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | SLC6A2 2094/4885SLC6A4 2292/4885SLC6A3 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.